N
ONCT

Nuveen’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Nuveen’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,468
Closed -$346K – 3555
2022
Q1 		$346K Buy
11,468
+176
+2% +$6.41K ﹤0.01% 3096
2021
Q4 		$551K Sell
11,292
-1,015
-8% -$68.3K ﹤0.01% 3053
2021
Q3 		$1.04M Buy
12,307
+1,992
+19% +$165K ﹤0.01% 2976
2021
Q2 		$980K Buy
+10,315
New +$1.22M ﹤0.01% 3014

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Nuveen's ONCT Position: Q2 2022 in Review

Nuveen sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2022, closing a stake of 11,468 shares — an estimated $346K sold.

Nuveen first reported a position in ONCT in Q2 2021 and held it in 4 quarters. The position peaked at $1.04M in Q3 2021. 75 funds tracked by Wall St. Rank hold ONCT as of Q2 2022.

  • Nuveen reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 11,468 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $346K.
  • Nuveen first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Nuveen's Oncternal Therapeutics, Inc. Common Stock position peaked at $1.04M in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.